A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
BeiGene
Genmab
Genmab
Genmab
Cyteir Therapeutics, Inc.
LaNova Medicines Limited
Celgene
Pfizer
Altor BioScience
AbbVie
AbbVie
MedImmune LLC
Seagen Inc.
Gilead Sciences
Seagen Inc.
GlaxoSmithKline
GlaxoSmithKline
Ascenta Therapeutics